[Treatment outcome of hematopoietic stem cell transplantation for myelodysplastic syndrome].
Tojyo
Arinobu
A
D000367:Age Factors; D036101:Cord Blood Stem Cell Transplantation; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D006648:Histocompatibility; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000601:surgery*; D017410:Practice Guidelines as Topic; D012306:Risk; D014019:Tissue Donors; D019172:Transplantation Conditioning; D016896:Treatment Outcome
D006680:HLA Antigens